Atrium Therapeutics Inc Revenue Growth Rates (RNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Atrium Therapeutics Inc   (NASDAQ: RNA)
 

RNA's Revenue Growth by Quarter and Year

Atrium Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 3.00
1st Quarter March 19.64
FY 22.64

RNAs Annual Revenue
Atrium Therapeutics Inc 's Revenue in the fiscal year 2025 $ 18.76 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2024 $ 10.90 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2023 $ 9.56 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2022 $ 9.22 millions
Atrium Therapeutics Inc 's Revenue in the fiscal year 2021 $ 9.33 millions




RNA Revenue second quarter 2026 Y/Y Growth Comment
Atrium Therapeutics Inc reported decline in Revenue in the second quarter 2026 by -21.97% to $ 3.00 millions, from the same quarter in 2025.
The contraction in the second quarter 2026 Atrium Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 104.33%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Revenue growth. While Atrium Therapeutics Inc ' s Revenue fall of -21.97% ranks overall at the positon no. 3545 in the second quarter 2026.


RNA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -71.04 % 35.62 % -20.94 %
3rd Quarter September - 433.33 % -17.02 % 13.71 %
2nd Quarter June -21.97 % 87.8 % -11.64 % 6.42 %
1st Quarter March 1150.96 % -55.65 % 58.74 % 23.89 %
FY   - 72.11 % 14.02 % -

Financial Statements
Atrium Therapeutics Inc 's second quarter 2026 Revenue $ 3.00 millions RNA's Income Statement
Atrium Therapeutics Inc 's second quarter 2025 Revenue $ 3.85 millions Quarterly RNA's Income Statement


RNA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -93.11 % 26.92 % -22.34 %
3rd Quarter September - 224.16 % 14.15 % 21.55 %
2nd Quarter June -84.7 % 145.22 % -42.09 % 4.04 %
1st Quarter March 2183.72 % -47.14 % 61.64 % -19.49 %
FY (Year on Year)   - 72.11 % 14.02 % -


Back to RNA Growth rate Comparisons >> Back to RNA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #488
Overall #3545

Revenue Y/Y Growth Statistics
High Average Low
1148.25 % 104.33 % -71.07 %
(Mar 31 2026)   (Mar 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #488
Overall #3545
Revenue Y/Y Growth Statistics
High Average Low
1148.25 % 104.33 % -71.07 %
(Mar 31 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Atrium Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2183.14 % 98.67 % -93.11 %
(Mar 31 2026)  


RNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Atrium Therapeutics Inc disclosed fall in Revenue from the first quarter by -84.7% to $ 3.00 millions, from $ 19.64 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 204 other companies have achieved higher Revenue quarter on quarter growth. While Atrium Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3862.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #205
Healthcare Sector #575
Overall #3862
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #205
Healthcare Sector #575
Overall #3862
Revenue Q/Q Growth Statistics
High Average Low
2183.14 % 98.67 % -93.11 %
(Mar 31 2026)  


RNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Atrium Therapeutics Inc disclosed fall in Revenue from the first quarter by -84.7% to $ 3.00 millions, from $ 19.64 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 204 other companies have achieved higher Revenue quarter on quarter growth. While Atrium Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3862.


Atrium Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 35.97 $ 36.82 $ 18.76 $ 20.87 $ 10.73
Y / Y Revenue Growth (TTM) 235.3 % 312.42 % 72.11 % 106.27 % 1.23 %
Year on Year Revenue Growth Overall Ranking # 3320 # 3282 # 397 # 0 # 535
Seqeuential Revenue Change (TTM) -2.29 % 96.3 % -10.13 % 94.5 % 20.19 %
Seq. Revenue Growth (TTM) Overall Ranking # 3322 # 3221 # 2678 # 0 # 855


Cumulative Revenue growth Comment
Assuming the Atrium Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Atrium Therapeutics Inc would have reprted above average annual Revenue surge of 235.3% year on year, of $ 36 millions.
This marks a slow-down of the companys growth trends and from the 312.42% surge in Mar 31 2026.

In the Healthcare sector 449 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3282 to 3320.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 450
Overall # 3320

Revenue TTM Y/Y Growth Statistics
High Average Low
312.42 %
 40.38 %
-17.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 450
S&P 500 # 3322
Cumulative Revenue growth Comment
Assuming the Atrium Therapeutics Inc 's fiscal year would have ended in Jun 30 2026, Atrium Therapeutics Inc would have reprted above average annual Revenue surge of 235.3% year on year, of $ 36 millions.
This marks a slow-down of the companys growth trends and from the 312.42% surge in Mar 31 2026.

In the Healthcare sector 449 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3282 to 3320.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 450
Overall # 3320

Revenue TTM Y/Y Growth Statistics
High Average Low
312.42 %
40.38 %
-17.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 149
Sector # 450
S&P 500 # 3322




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RNA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Atrium Therapeutics Inc Revenue Growth Rates (RNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Avidity Biosciences Inc (CIK 1599901).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001599901-26-000031
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Avidity Biosciences Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.